THE DEAL, AT A GLANCE
From the announcementPairidex
01What it doesFusionMRD™ is now commercially available as a laboratory-developed test (LDT) in Pairidex’s CAP accredited/CLIA certified lab.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02Who is involvedBacked by BlueLake, product developmentFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedPairidex raised $4.9M Seed, announced 2026-08-25From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersPairidex is using Seed financing to move FusionMRD™ from product development into commercialization as a peripheral blood-based MRD test for acute myeloid leukemia.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Pairidex · Financing Record
Explore source-linked visual explanations for Pairidex. Unsupported claims are withheld while source review continues.
Record 10965 · Recorded date: 2026-08-25
Explore company records →